New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia.
Cannabis consumption may induce psychotic states in normal individuals, worsen psychotic symptoms of schizophrenic patients, and may facilitate precipitation of schizophrenia in vulnerable individuals. Recent studies provide additional biological and genetic evidence for the cannabinoid hypothesis of schizophrenia. Examinations using [3H]CP-55940 or [3H]SR141716A revealed that the density of CB1 receptors, a central type of cannabinoid receptor, is increased in subregions of the prefrontal cortex in schizophrenia. Anandamide, an endogenous cannabinoid, is also increased in the CSF in schizophrenia. A genetic study revealed that the CNR1 gene, which encodes CB1 receptors, is associated with schizophrenia, especially the hebephrenic type. Individuals with a 9-repeat allele of an AAT-repeat polymorphism of the gene may have a 2.3-fold higher susceptibility to schizophrenia. Recent findings consistently indicate that hyperactivity of the central cannabinoid system is involved in the pathogenesis of schizophrenia or the neural mechanisms of negative symptoms.
Ujike
Hiroshi
H
Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. hujike@cc.okayama-u.ac.jp
Morita
Yukitaka
Y
D000581:Amidohydrolases / Q000235:genetics; D063385:Cannabinoid Receptor Modulators / Q000134:cerebrospinal fluid; D063388:Endocannabinoids; D006801:Humans; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics / Q000502:physiology*; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000209:etiology* / Q000235:genetics; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D043884:Receptor, Cannabinoid, CB1; D000099252:Fatty Acid Amide Hydrolases